Spruce Biosciences, Inc.

NASDAQ:SPRB

Biotechnology

Healthcare
$40.49 +5.07%

+$2.47 today

Market cap
$116.37M
Beta
3.20
P/E (TTM)
-1.9
EPS (TTM)
-$27.11
52W Low $7.00High $838.13

Volume 0.05M

Average 0.06M

Returns on capital

Spruce Biosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-91.7%

avg -45.6%

ROIC

-84.4%

avg -215.3%

ROA

-73.5%

avg -103.9%

Analysis

ROA is currently the strongest return metric at -73.5% versus its period average of -103.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Javier Szwarcberg

Chief Executive Officer & DirectorUSD 1.12M56——

Samir Gharib

President & Chief Financial OfficerUSD 784.04K44——

Adrian Quartel FFPM

Chief Medical OfficerUSD 647.4K65——

Kirk Ways

DirectorUSD 596.83K7430.00K2.19%

Michael G. Grey

Executive ChairmanUSD 70K731.70K0.12%

Daven Mody

Senior Vice President of Regulatory & Quality————

Corwin Dale Hooks

Chief Commercial Officer—590<0.01%

Eric Jordan

Vice President of Marketing————

Saba Sile

Senior Vice President of Clinical Development————

Tina Gullotta

Vice President of Finance and Corporate Controller—52——

Bruno Gagnon BPHARM

Senior Vice President of Clinical Development Operations—57——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 21, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Spruce Biosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SPRB's management, answered from reported figures.

Who manages SPRB?

Spruce Biosciences, Inc. (SPRB) lists 11 active executives. The top listed executive is Adrian Quartel FFPM, Chief Medical Officer.

Are SPRB insiders buying or selling?

Recent insider activity shows net buying of $10.07M.